Cartography Biosciences Launches With USD57M in Funding
Summary
Cartography Biosciences, a Foster City, CA-based precision medicine company creating therapeutics guided by comprehensive antigen atlas for immuno-oncology targets, launched with $57 million in initial funding. Led by CEO Kevin Parker, Ph.D., who founded the company alongside noted Stanford University physician-scientist-entrepreneurs Ansu Satpathy, M.D., Ph.D., and Howard Chang, M.D., Ph.D., who each head world-renowned genomics laboratories, Cartography has developed a platform that integrates computational and experimental techniques, including single-cell genomics and proteomics, with high-throughput binder discovery capabilities. Their cell-by-cell atlas identifies optimal antigens by predicting both efficacy and off-target effects for binders against that target. Cartography is using its modality-agnostic antigen profiling platform as a roadmap to create novel immunotherapies by identifying the targets that maximize efficacy while minimizing potentially toxic side effects. The company’s Scientific Advisory Board is led by Carl June, M.D., along with Emma Lundberg, Ph.D., Angela Shen, M.D., M.B.A., and Joseph Fraietta, Ph.D.